Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY21
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Caplin Point Laboratories Ltd (CAPLIPOINT) is currently trading at 1,658.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Caplin Point Laboratories is an India‑headquartered pharmaceutical company focused on developing, manufacturing and exporting a broad portfolio of generic formulations and sterile injectables to Latin America, Africa and regulated markets including the US and EU through subsidiaries such as Caplin Steriles and regional distribution units. Management reports an active and expanding US ANDA pipeline with recent first‑cycle approvals for complex suspension injectables and ophthalmic emulsions, a growing US label business approaching ~$10 million since inception, and an expectation of several more ANDA approvals and launches across FY26–FY28. The company is mid‑way through a substantive capacity build‑out (Phase 3 injectable lines, ophthalmic, pre‑filled syringes and blow‑fill‑seal technology) plus a Vizag API plant for backward integration, positioning Caplin Point Laboratories to increase self‑reliance and reduce external API exposure over the medium term. Financially Caplin delivered steady growth with nine‑month revenue up ~10.6% YoY, PAT margin near 28.5%, strong free cash generation and INR 1,381 crore of cash and equivalents, enabling continued capex funding, selective inorganic bolt‑ons and a war chest for opportunistic acquisitions. Compliance and operational rigor are being institutionalized via video SOPs (visual SOPs) with planned AI governance and a filed patent, and the company has cleared recent EU GMP and Saudi FDA audits without critical observations, highlighting its regulatory readiness for expanded exports.
Over the past 52 weeks, Caplin Point Laboratories Ltd has traded between a low of ₹1,551.05 and a high of ₹2,396.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Caplin Point Laboratories Ltd has a market capitalization of approximately 12,732.34. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Caplin Point Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.96 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 12,732.34 Cr, Caplin Point Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Caplin Point Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Caplin Point Laboratories Ltd is 20.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The ₹10,000 crore scheme builds a domestic ecosystem for biologics and biosimilars, providing Caplin Point with better R&D infrastructure, talent from new NIPERs, and a network of clinical trial sites.
Regulatory Approval
Caplin Steriles (subsidiary of Caplin Point) received final USFDA approval for its ANDA for Desmopressin Acetate Injection USP (4 mcg/mL single-dose and 40 mcg/10 mL multi-dose vials), a generic of DDAVP; US market sales ~USD 26M (12 months to Dec 2025).
USFDA Approval
Caplin Steriles, a subsidiary of Caplin Point, received USFDA final approval for its ANDA for Desmopressin Acetate Injection USP (4 mcg/mL single‑dose and 40 mcg/10 mL multi‑dose), a generic of DDAVP; US sales ~ $26M (12m to Dec‑2025).
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
996.85 | 21,089 Cr | 64.06 | 9.29 | 0.00 | 12.62 | 16.34 | 9.99 | |
1369.00 | 18,886 Cr | 43.26 | 5.37 | 0.53 | 13.45 | 14.38 | 6.57 | |
1686.70 | 12,732 Cr | 20.96 | 4.03 | 0.36 | 18.64 | 23.29 | 17.76 | |
770.25 | 12,671 Cr | 88.74 | 11.04 | 0.00 | 26.49 | 22.49 | 11.57 | |
172.80 | 7,769 Cr | 21.71 | 2.89 | 0.47 | 13.08 | 16.13 | 10.51 | |
324.75 | 6,330 Cr | 39.39 | 2.60 | 0.15 | 6.35 | 8.41 | 4.29 | |
126.85 | 4,091 Cr | -15.36 | 0.00 | 0.00 | 77.47 | -181.73 | -83.09 |
Bearish
3
Neutral
5
Bullish
6
Bearish
35
Neutral
5
Bullish
6
Bearish
32
Neutral
0
Bullish
0
Caplin Point Laboratories is an India‑headquartered pharmaceutical company focused on developing, manufacturing and exporting a broad portfolio of generic formulations and sterile injectables to Latin America, Africa and regulated markets including the US and EU through subsidiaries such as Caplin Steriles and regional distribution units.
Management reports an active and expanding US ANDA pipeline with recent first‑cycle approvals for complex suspension injectables and ophthalmic emulsions, a growing US label business approaching ~$10 million since inception, and an expectation of several more ANDA approvals and launches across FY26–FY28.
The company is mid‑way through a substantive capacity build‑out (Phase 3 injectable lines, ophthalmic, pre‑filled syringes and blow‑fill‑seal technology) plus a Vizag API plant for backward integration, positioning Caplin Point Laboratories to increase self‑reliance and reduce external API exposure over the medium term.
Financially Caplin delivered steady growth with nine‑month revenue up ~10.6% YoY, PAT margin near 28.5%, strong free cash generation and INR 1,381 crore of cash and equivalents, enabling continued capex funding, selective inorganic bolt‑ons and a war chest for opportunistic acquisitions.
Compliance and operational rigor are being institutionalized via video SOPs (visual SOPs) with planned AI governance and a filed patent, and the company has cleared recent EU GMP and Saudi FDA audits without critical observations, highlighting its regulatory readiness for expanded exports.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
12,732 Cr
Moderate Risk
21.0
44.0
2.2
4.0
2,396.95
1,551.05
Sales CAGR
Profit CAGR
ROE
ROCE
